Actively Recruiting
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Led by Bernstein Clinical Research Center · Updated on 2025-02-25
5
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
use of lanadelumab in patients with acquired angioedema
CONDITIONS
Official Title
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of acquired angioedema with recurrent attacks without hives, confirmed by decreased C1INH functional and quantitative levels, decreased C4 and C1q levels, no family history of angioedema, and presence of anti-C1INH antibody and/or paraproteinemia (e.g., monoclonal gammopathy of unknown significance)
- History of at least one attack per month before starting tranexamic acid treatment
You will not qualify if you...
- History of anaphylaxis or hypersensitivity to biological therapies
- Major systemic disease not well controlled as judged by the principal investigator
- Women who are pregnant or breastfeeding
- Participation in other clinical trials
- Diagnosis of hereditary angioedema Type 1 or 2 or normal complement hereditary angioedema
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States, 45236
Actively Recruiting
Research Team
K
Karen Berendts
CONTACT
J
Jonathan Bernstein, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here